In separate major multicenter trials, two novel valve systems proved effective in severe mitral valve diseases for which there are limited or no options.

At the upcoming ASH annual meeting, the Company will detail secondary endpoints, such as GI-ORR at D56 and Month 3 (M3), and some safety data. Final results, including 1-year overall survival, are ...

A new, illuminating report from Credence Research indicates that the Global Luxury Lighting Market is on a significant growth trajectory, transforming from a functional necessity into a central ...

Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific” or the “Company”) today reported its financial results for the quarter ended September 30, 2025. Net Income of $262.6 million, or $5.16 per ...